Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting
20 Giugno 2024 - 11:34PM
Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a
biopharmaceutical company committed to advancing new cancer
therapies based on novel DNA-damage response technologies, is
pleased to announce, further to the press release dated May 23,
2024, that it has received subscriptions totalling $1.7 million for
its previously announced $1.5 million private placement. The terms
of the private placement otherwise remain unchanged. To accommodate
additional interest, the Company will upsize the financing to $2.0
Million, subject to TSX-V approval. The Company anticipates a first
closing of the private placement on or about June 25, 2024.
“Rakovina Therapeutics has benefited greatly from the support of
our long-term shareholders. With this financing we are pleased to
welcome a new group of investors to the Company,” said Rakovina
Therapeutics’ Executive Chairman, Jeffrey Bacha.
“These funds will be used to further accelerate research
activities related to our recently announced AI drug-discovery
partnership and expanded collaboration with the University of
British Columbia and Pharma Inventor Inc. We remain steadfast in
our mission to develop new treatments to improve the lives of those
affected by cancer,” he added.
AGM ElectionsThe Company is also pleased to
announce the results of voting at its 2024 annual general meeting
of shareholders held on June 20, 2024, in Vancouver, British
Columbia (the “Meeting”).
All four members of the Company’s board of directors named as
nominees in its management information circular dated May 20, 2024
(the “Circular”) were re-elected as directors: Jeffrey Bacha, Dr.
Dennis Brown, Alfredo De Lucrezia and Michael Liggett.
In addition, at the Meeting, the shareholders of the Company:
(i) approved the re-appointment of Davidson & Company LLP as
the Company’s auditor until the next annual general meeting of
shareholders; and (ii) re-approved the Company’s existing omnibus
equity incentive plan as set out in the Circular.
About Rakovina Therapeutics Inc.Rakovina
Therapeutics Inc. is focused on the development of new cancer
treatments based on novel DNA-damage response technologies. The
Company has established a pipeline of novel DNA-damage response
inhibitors with the goal of advancing one or more drug candidates
into human clinical trials and obtaining marketing approval for new
cancer therapeutics from Health Canada, the United States Food and
Drug Administration and similar international regulatory agencies.
Further information may be found at
www.rakovinatherapeutics.com.
The TSXV has neither approved nor disapproved the content of
this press release. Neither the TSXV nor its Regulation Services
Provider (as that term is defined in policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this release.
Notice Regarding Forward-Looking
Statements:This release includes forward-looking
statements regarding the Company and its respective business, which
may include, but is not limited to, statements with respect to the
closing of the private placement, the proposed business plan of the
Company and other statements. Often, but not always,
forward-looking statements can be identified by the use of words
such as “plans”, “is expected”, “expects”, “scheduled”, “intends”,
“contemplates”, “anticipates”, “believes”, “proposes” or variations
(including negative variations) of such words and phrases, or state
that certain actions, events, or results “may”, “could”, “would”,
“might” or “will” be taken, occur or be achieved. Such statements
are based on the current expectations of the management of the
Company. The forward-looking events and circumstances discussed in
this release may not occur by certain specified dates or at all and
could differ materially as a result of known and unknown risk
factors and uncertainties affecting the Company, including risks
regarding the medical device industry, economic factors, regulatory
factors and the need for regulatory approval, the equity markets
generally and risks associated with growth and competition.
Although the Company has attempted to identify important factors
that could cause actual actions, events, or results to differ
materially from those described in forward-looking statements,
there may be other factors that cause actions, events, or results
to differ from those anticipated, estimated or intended. No
forward-looking statement can be guaranteed. Except as required by
applicable securities laws, forward-looking statements speak only
as of the date on which they are made and the Company undertakes no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events,
or otherwise. The reader is referred to the Company’s most
recent filings on SEDAR for a more complete discussion of all
applicable risk factors and their potential effects, copies of
which may be accessed through the Company’s profile page at
www.sedar.com.
For Further Information Contact:David Hyman,
Chief Financial Officerinfo@rakovinatehrapeutics.com
Invest Relations & MediaIra M.
Gostinir@rakovinatherapeutics.com775-391-0213
Grafico Azioni Rakovina Therapeutics (TSXV:RKV)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni Rakovina Therapeutics (TSXV:RKV)
Storico
Da Mar 2024 a Mar 2025